Their main focus is on idiopathic pulmonary fibrosis (IPF), a fatal lung disease, for which they have developed Pirfenidone, the only approved medicine for IPF worldwide. InterMune's research programs aim to discover targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company is driven by values such as integrity, passion, accountability, creativity, and teamwork, with the ultimate goal of bringing new treatments and hope to patients and families worldwide.